Medullary Thyroid Cancer Clinical Trial
Official title:
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
The reason for this study is to see if the study drug selpercatinib is safe and more effective compared to a standard treatment in participants with rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC) that cannot be removed by surgery or has spread to other parts of the body. Participants who are assigned to the standard treatment and discontinue due to progressive disease have the option to potentially crossover to selpercatinib.
Adaptive sample size re-estimation will be performed at interim analysis. The sample size could be increased from approximately 250 to 400 depending on the results of interim analysis. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03643055 -
18F-Fluorocholine PET/CT in Medullary Thyroid Cancer
|
||
| Terminated |
NCT02709889 -
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06277180 -
68Ga-TCR-FAPI PET/CT Guided Precision Surgery for MTC
|
N/A | |
| Withdrawn |
NCT04760288 -
A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).
|
Phase 3 | |
| Not yet recruiting |
NCT06079723 -
A Detailed Look At What Patients Experience In Medullary Thyroid Cancer Clinical Study
|
||
| Recruiting |
NCT01739634 -
The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03157128 -
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
|
Phase 1/Phase 2 | |
| Completed |
NCT02856347 -
Prospective Study Evaluating the Medullary Thyroid Cancer Management's Care Using PET F-DOPA in Patients With a High Level of Postoperative Residual Thyrocalcitonin
|
N/A | |
| Completed |
NCT03037385 -
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04280081 -
A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation
|
Phase 2 | |
| Not yet recruiting |
NCT06292988 -
Predictive Factors for Medullary Thyroid Cancer Aggressiveness
|
||
| Completed |
NCT01757470 -
Vandetanib Risk Minimisation Effectiveness
|
N/A | |
| Recruiting |
NCT05830500 -
Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma
|
Phase 4 | |
| Recruiting |
NCT03899792 -
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT01660984 -
Natural History Study of Children and Adults With Medullary Thyroid Cancer
|
||
| Withdrawn |
NCT03838692 -
Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer
|
Phase 2 | |
| Terminated |
NCT02363647 -
Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid or Metastatic Colon Cancer
|
N/A | |
| Terminated |
NCT00582712 -
An Initial Study of Lithium in Patients With Medullary Thyroid Cancer
|
Phase 2 | |
| Recruiting |
NCT06141369 -
Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)
|
N/A | |
| Completed |
NCT06243965 -
Is Desmoplastic Stromal Reaction Useful to Modulate Lymph Node Dissection in Sporadic Medullary Thyroid Carcinoma?
|